Pasithea Therapeutics Corp.
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2022
- $486.6K
- Net income
- -$20.4M
- Total assets
- $60.2M
- Market cap
- $19.5M
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Operating income
- -$20.9M
- Net income
- -$20.4M
- EPS (basic)
- $-2.91
- EPS (diluted)
- $-2.91
Balance sheet
- Total assets
- $60.2M
- Current assets
- $56.5M
- Total liabilities
- $5.0M
- Current liabilities
- $5.0M
- Shareholders’ equity
- $55.2M
Cash flow
- Operating cash flow
- -$15.2M
- Investing cash flow
- $11.0K
- Financing cash flow
- $63.5M
- Net cash flow
- $48.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $19.5M
- EPS (diluted)
- $-2.91
- Shares outstanding
- 33.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 15, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $20.4M in FY2022.
- Trading 62% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Pasithea Therapeutics Corp..
Write a review
News about Pasithea Therapeutics Corp.
News & sentiment via Polygon.io
